menu
    • menu
    [{"orgOrder":0,"company":"4M Therapeutics","sponsor":"SynGAP Research Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ SynGAP Research Fund","highestDevelopmentStatusID":"4","companyTruncated":"4M Therapeutics \/ SynGAP Research Fund"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"4M Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"4MT2001","moa":"GSK-3-beta","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"4M Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by 4M Therapeutics

    Menu

    4M Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            4M Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            4M Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 4MT2001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            4M Therapeutics Reports Positive Results from 4MT2001 GLP Safety Studies

                            Details : 4MT2001, a novel small molecule glycogen synthase kinase 3 beta (GSK3β) inhibitor, that demonstrated clear central nervous system (CNS) target engagement.

                            Product Name : 4MT2001

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 11, 2025

                            Lead Product(s) : 4MT2001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            4M Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            4M Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 4MT2001

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : SynGAP Research Fund

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            4M Therapeutics Awarded $120K Grant for Preclinical SYNGAP1 Research

                            Details : The proceeds will be used to evaluate central nervous system effects of novel glycogen synthase kinase 3 beta inhibitors 4MT2001 and 4MT1060 in preclinical SYNGAP1-related disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : 4MT2001

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : SynGAP Research Fund

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            4M Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            4M Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 4MT2001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            4M Therapeutics Reports Positive Preclinical Data for CNS Targeting Asset 4MT2001

                            Details : 4MT2001, a novel small molecule glycogen synthase kinase 3 beta inhibitor, that demonstrated clear central nervous system (CNS) target engagement paralleling its positive effects on animal behavior.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 09, 2024

                            Lead Product(s) : 4MT2001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth